Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype
- PMID: 1569189
- PMCID: PMC443023
- DOI: 10.1172/JCI115743
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype
Abstract
We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. This oncogene, papillary thyroid carcinoma (PTC), is a novel rearranged version of the ret tyrosine-kinase protooncogene. Thyroid neoplasms include a broad spectrum of malignant tumors, ranging from well-differentiated tumors to undifferentiated anaplastic carcinomas. To determine the frequency of ret oncogene activation, we analyzed 286 cases of human thyroid tumors of diverse histologic types. We found the presence of an activated form of the ret oncogene in 33 (19%) of 177 papillary carcinomas. By contrast, none of the other 109 thyroid tumors, which included 37 follicular, 15 anaplastic, and 18 medullary carcinomas, and 34 benign lesions, showed ret activation.
Similar articles
-
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma.Oncogene. 1994 Feb;9(2):509-16. Oncogene. 1994. PMID: 8290261
-
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.Clin Cancer Res. 1998 Feb;4(2):287-94. Clin Cancer Res. 1998. PMID: 9516913
-
Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors.Endocrinol Jpn. 1991 Dec;38(6):627-32. doi: 10.1507/endocrj1954.38.627. Endocrinol Jpn. 1991. PMID: 1823030
-
The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.Virchows Arch. 1997 Jul;431(1):1-9. doi: 10.1007/s004280050062. Virchows Arch. 1997. PMID: 9247627 Review.
-
Oncogenes and thyroid cancer.Clin Chem Lab Med. 2000 Feb;38(2):113-6. doi: 10.1515/CCLM.2000.017. Clin Chem Lab Med. 2000. PMID: 10834397 Review.
Cited by
-
Harnessing Immunity to Treat Advanced Thyroid Cancer.Vaccines (Basel). 2023 Dec 30;12(1):45. doi: 10.3390/vaccines12010045. Vaccines (Basel). 2023. PMID: 38250858 Free PMC article. Review.
-
Genomic alterations in thyroid cancer: biological and clinical insights.Nat Rev Endocrinol. 2024 Feb;20(2):93-110. doi: 10.1038/s41574-023-00920-6. Epub 2023 Dec 4. Nat Rev Endocrinol. 2024. PMID: 38049644 Review.
-
Update on Molecular Diagnostics in Thyroid Pathology: A Review.Genes (Basel). 2023 Jun 22;14(7):1314. doi: 10.3390/genes14071314. Genes (Basel). 2023. PMID: 37510219 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
RET Proto-Oncogene Mutational Analysis in 45 Iranian Patients Affected with Medullary Thyroid Carcinoma: Report of a New Variant.J Thyroid Res. 2021 Nov 3;2021:7250870. doi: 10.1155/2021/7250870. eCollection 2021. J Thyroid Res. 2021. PMID: 34777782 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
